GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (FRA:4DN) » Definitions » Float Percentage Of Total Shares Outstanding

Denali Therapeutics (FRA:4DN) Float Percentage Of Total Shares Outstanding : 85.37% (As of Sep. 20, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Denali Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Denali Therapeutics's float shares is 122.23 Mil. Denali Therapeutics's total shares outstanding is 143.17 Mil. Denali Therapeutics's float percentage of total shares outstanding is 85.37%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Denali Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Denali Therapeutics's Institutional Ownership is 55.54%.

Denali Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Denali Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=122.23/143.17
=85.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Denali Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Denali Therapeutics Inc (FRA:4DN) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ARWR MDGL MLTX FTRE RARE DNA CORT AXSM BHVN TRML OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
DNLI:USA 4DN:Germany
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Website
https://www.denalitherapeutics.com
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics Headlines

No Headlines